Publication

Video

Supplements and Featured Publications

Milestones in Medicine: Updates in BPDCN
Volume1
Issue 1

Dr. Wang on the Current Treatment Options for BPDCN

Author(s):

Eunice Wang, MD, discusses the current treatment options for blastic plasmacytoid dendritic cell neoplasm.

Eunice Wang, MD, chief the Leukemia Service, the Department of Medicine, Roswell Park Comprehensive Cancer Center, discusses the current treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Up-front treatment for patients with BPDCN includes tagraxofusp-erzs (Elzonris), a therapy designed to target CD-123, which is highly expressed in BPDCN and other hematologic malignancies, Wang explains. 

Although effective, tagraxofusp is also associated with certain adverse effects, and it is important to be mindful of these toxicities, particularly with regard to elderly patients with BPDCN, Wang adds. Patients receiving tagraxofusp should have preserved functional status and an acceptable serum albumin level, Wang says. If patients do not have meet these criteria, tagraxofusp can cause capillary leak syndrome, leading to hypotension or acute drops in blood pressure, according to Wang.

Patients who are not candidates to receive tagraxofusp, including those who are too sick or too elderly, should be considered for experimental therapies or alternative treatment regimens that may not be as effective, but are better tolerated, Wang concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity